Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Aim Immunotech Inc (AIM)

Aim Immunotech Inc (AIM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,991
  • Shares Outstanding, K 8,148
  • Annual Sales, $ 90 K
  • Annual Income, $ -13,960 K
  • EBIT $ -12 M
  • EBITDA $ -10 M
  • 60-Month Beta 1.36
  • Price/Sales 50.48
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -9.44
  • Most Recent Earnings $-0.44 on 03/27/26
  • Next Earnings Date 05/21/26
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Drugs

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-1.08
  • Number of Estimates 1
  • High Estimate $-1.08
  • Low Estimate $-1.08
  • Prior Year $-5.00
  • Growth Rate Est. (year over year) +78.40%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.4750 +2.74%
on 04/20/26
1.0500 -53.52%
on 03/24/26
-0.4709 (-49.11%)
since 03/20/26
3-Month
0.4750 +2.74%
on 04/20/26
1.8799 -74.04%
on 02/05/26
-0.6820 (-58.29%)
since 01/21/26
52-Week
0.4750 +2.74%
on 04/20/26
20.3500 -97.60%
on 07/28/25
-2.8620 (-85.43%)
since 04/21/25

Most Recent Stories

More News
AIM ImmunoTech Enters Pivotal Value Inflection Phase with Planned Phase 3 Study of Ampligen® in Pancreatic Cancer, Backed by Positive Clinical Signals, Orphan Drug Status, and Global IP

Company to participate in Live Virtual Investor Closing Bell segment today, April 16 th  at 4:00 PM ET ; Register for the event  here OCALA, Fla., April 16, 2026 (GLOBE NEWSWIRE) --...

AIM : 0.4880 (-0.37%)
AIM ImmunoTech Provides Routine Update on Annual Filings

OCALA, Fla., April 13, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM)  (“AIM” or the “Company”) today advised that its audited consolidated financial statements for the...

AIM : 0.4880 (-0.37%)
AIM ImmunoTech to Participate in Live Virtual Investor Closing Bell Event

Live video webcast with Tom Equels, Chief Executive Officer of AIM ImmunoTech, on Thursday, April 16 th  at 4:00 PM ET   Register for the event here OCALA, Fla., April 09, 2026 (GLOBE...

AIM : 0.4880 (-0.37%)
accesso® Acquires Dexibit®, Establishing the First Cross Platform AI and Analytics Platform for Visitor Attractions

Acquisition launches accesso Intelligence SM , connecting guest and operator data, insight and action across the entire operation

AIM : 0.4880 (-0.37%)
accesso® Acquires Dexibit®, Establishing the First Cross Platform AI and Analytics Platform for Visitor Attractions

Acquisition launches accesso Intelligence SM , connecting guest and operator data, insight and action across the entire operation

AIM : 0.4880 (-0.37%)
AIM ImmunoTech Announces Final Approval of Novel Cancer Therapy Patent in Japan Combining Ampligen with Checkpoint Inhibitors

OCALA, Fla., March 18, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM)  (“AIM” or the “Company”) today announced that the Japan Patent Office has fully approved a Japanese...

AIM : 0.4880 (-0.37%)
AIM ImmunoTech Announces Closing of its Rights Offering

OCALA, Fla., March 06, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) – AIM ImmunoTech Inc. (“AIM” or the “Company”), an immuno-pharma company focused on the research and...

AIM : 0.4880 (-0.37%)
AIM ImmunoTech Announces Expiration and Preliminary Results of its Rights Offering for Aggregate Gross Proceeds of $1.8 Million

OCALA, Fla., March 04, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) – AIM ImmunoTech Inc. (“AIM” or the “Company”), an immuno-pharma company focused on the research and...

AIM : 0.4880 (-0.37%)
AIM ImmunoTech Signs Agreement for Planning of a Proposed Phase 3 Clinical Trial of Ampligen in the Treatment of Late-Stage Pancreatic Cancer

OCALA, Fla., March 02, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM)  (“AIM” or the “Company”) today announced an agreement with the PPD™ clinical research business...

AIM : 0.4880 (-0.37%)
AIM ImmunoTech Reminds Stockholders of March 3, 2026 Expiration Date and Updates Terms of Previously Announced Rights Offering

OCALA, Fla., Feb. 27, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) – AIM ImmunoTech Inc. (“AIM” or the “Company”), an immuno-pharma company focused on the research and...

AIM : 0.4880 (-0.37%)

Business Summary

AIM ImmunoTech Inc. is an immuno-pharma company. It is focused on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency diseases. The company's flagship products include Ampligen(R), Rintamod(R) and Alferon N Injection(R) which are in clinical stage. AIM...

See More

Key Turning Points

3rd Resistance Point 0.5349
2nd Resistance Point 0.5207
1st Resistance Point 0.5043
Last Price 0.4880
1st Support Level 0.4737
2nd Support Level 0.4595
3rd Support Level 0.4431

See More

52-Week High 20.3500
Fibonacci 61.8% 12.7577
Fibonacci 50% 10.4125
Fibonacci 38.2% 8.0673
Last Price 0.4880
52-Week Low 0.4750

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.